Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 5; p. 211
Main Authors Mahner, Sven, Woelber, Linn, Mueller, Volkmar, Witzel, Isabell, Prieske, Katharina, Grimm, Donata, Keller-V Amsberg, Gunhild, Trillsch, Fabian
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.10.2015
Subjects
Oncology
anti-angiogenic therapy
multikinase inhibitors
trebananib
ovarian cancer
nintedanib
cediranib
pazopanib
Online AccessGet full text

Cover

More Information
Summary:In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib were developed to interfere with VEGF receptors and multiple additional intracellular pathways. Nintedanib and pazopanib significantly improved progression-free survival in two positive phase III trials for first-line therapy. A reliable effect on overall survival could, however, not be observed for any anti-angiogenic first-line therapies so far. In terms of recurrent disease, two positive phase III trials revealed that trebananib and cediranib are effective anti-angiogenic agents for this indication. Patient selection and biomarker guided prediction of response seems to be a central aspect for future studies. Combining anti-angiogenics with other targeted therapies to possibly spare chemotherapy in certain constellations represents another very interesting future perspective for clinical trials. This short review gives an overview of current clinical trials for anti-angiogenic treatment strategies beyond bevacizumab. In this context, possible future perspectives combining anti-angiogenics with other targeted therapies and the need for specific biomarkers predicting response are elucidated.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Emily K. Colvin, University of Sydney, Australia; Connie Irene Diakos, University of Sydney, Australia
Present address: Sven Mahner, Department of Obstetrics and Gynaecology, University of Munich, Munich, Germany
Specialty section: This article was submitted to Women’s Cancer, a section of the journal Frontiers in Oncology
Edited by: Ana Oaknin, Vall d’Hebron Institute of Oncology, Spain
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2015.00211